Clinical Trials · NCT04348175

A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment

Name: A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1Setmelanotide

Phase: Phase 1
Recruitment status: Completed
Sponsor: Rhythm Pharmaceuticals, Inc.
Enrollment: 32
Start date: Jul 2020
Locations: 4 sites, United States
Primary endpoint: Pharmacokinetic Parameter - Peak Plasma Concentration (Cmax)

View Setmelanotide compound reference